World Coronavirus Dispatch: US stocks at new high over Moderna vaccine data

Hungary and Poland block EU stimulus package, Citi says successful vaccines will see dollar plummet, No virus protection for jailed elderly Taxes and other pandemic-related news across the globe

coronavirus, wall street, markets
American drug-maker Moderna reported that its experimental covid-19 vaccine is 94.5 percent effective in preventing the disease
Yuvraj Malik New Delhi
4 min read Last Updated : Nov 17 2020 | 2:07 PM IST
US stocks hit new record after Moderna vaccine data: Wall Street’s benchmark S&P 500 index ended the day up 1.2 per cent while the Russell 2000 of US small-cap stocks — seen as a barometer of the domestic economy — also closed at a record. The tech-heavy US Nasdaq Composite advanced a more modest 0.8 per cent. Hopes that a successful vaccine could be deployed to slow the spread of coronavirus in as little as a few months triggered a powerful rotation into economically sensitive sectors that began last week, as investors moved away from groups perceived as beneficiaries of the pandemic. Read more here

Let’s look at the global statistics:

Total Confirmed Cases: 54,992,571

Change Over Yesterday: 621,815

Total Deaths: 1,326,768

Total Recovered: 35,296,725

Nations hit with most cases: US (11,202,109), India (8,845,127), Brazil (5,876,464), France (2,041,293) and Russia (1,932,711)


Moderna says Covid vaccine shows nearly 95 percent protection: American drug-maker Moderna reported that its experimental covid-19 vaccine is 94.5 percent effective in preventing the disease (see main stories). The results of a late-stage trial, involving 30,000 American adults, came a week after Pfizer announced a similar level of efficacy for its jab. Moderna’s vaccine does not need to be stored at very cold temperatures, as Pfizer’s does. Read more here

Hungary and Poland block EU’s coronavirus stimulus package: Hungary and Poland on Monday blocked the European Union’s sprawling coronavirus stimulus package, protesting a provision that would withhold funding from member states that violate the bloc’s rule-of-law standards, an accusation regularly leveled against the two governments, which have spent years co-opting their nations’ judiciary systems. Read more here

US Supreme Court rejects request from elderly Texas prisoners for virus protections: The Supreme Court on Monday turned down a request from inmates in a Texas prison to take steps to protect them from the coronavirus pandemic. The case was brought by two prisoners said prison officials had not taken adequate steps to protect them, and that conditions at the prison violated the Constitution’s Eighth Amendment, which prohibits cruel and unusual punishments. Read more here

Experts worry US states’ plans to conduct own vaccine reviews could sow confusion: Half-dozen states and the District of Columbia have planned an extra layer of scrutiny: committees that would vet any vaccine reviewed by the FDA, a step many public health experts and officials deem unnecessary given a federal review process they describe as meticulous.
The committees — most of them in states led by Democratic governors — are in part a response to the Trump administration’s handling of the pandemic. Read more here

Citigroup says successful vaccines will send the dollar plummeting: “Vaccine distribution we believe will check off all of our bear market signposts, allowing the dollar to follow a similar path to that it experienced from the early to mid-2000s” when the currency started a multi-year downturn, Citigroup strategists including Calvin Tse wrote in a report. Strategists have been positing for months that the US election, vaccine breakthroughs and Federal Reserve policy could deal a serious blow to the currency. Read more here

Specials 

Explained: How Moderna’s Covid-19 vaccine stability eases distribution challenges
 
Moderna Inc’s experimental Covid-19 vaccine is more stable than expected at temperatures that ordinary refrigerators can provide and can be distributed using existing cold-chain shipping and storage infrastructure. Read more here

Getting out of your head and your house
 
Relish walking the dog or strolling without any particular destination. Volunteer to run to the store for flour, to drop a package off at the post office. Go for the outdoor run you could easily take to the treadmill. While I’d hardly suggest the era of sweatpants and comfort cooking is over, making an effort to be in fresh air while we can is still essential to keeping our days from assuming a rolling monotony. If you’re not able to go outdoors, try a different room, a new activity or recipe, something that shakes things up, that demarcates weekend from week. Read more here

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineCoronavirus TestsUS stocksWall StreetPfizer

Next Story